Pravin Kaumaya | Professor
Ohio State University

Pravin Kaumaya, Professor, Ohio State University

Dr Kaumaya is Professor of Medicine in the Department of Ob/Gyn at the OSU Wexner Medical Center and the James Comprehensive Cancer Center. Dr Kaumaya is internationally recognized as an expert in the fields of vaccine research with emphasis on peptide vaccines for cancer. His work over 3 decades in developing B-cell epitope-based cancer vaccines is a paradigm shift in the immune-oncology landscape. Dr. Kaumaya is an elected fellow of the American Association for the Advancement of Science (AAAS), and he was elected as the treasurer of the American Peptide Society since 2009. He has lectured worldwide and has published over 130 peer-reviewed articles in major scientific journals. He is an inventor on several issued and pending patents for peptide cancer vaccines and immune-therapeutic technologies. He conducts translational research from bench to the clinic with the goal of designing and developing new combination immunotherapies and immunologic strategies for cancer treatment and prevention. Dr Kaumaya’s laboratory has recently developed a PD-1-Vaxx B-cell peptide cancer vaccine and has also developed vaccines for PD-L1, CTLA-4, TIGIT, TIM3 and LAG-3 which will be developed as combination immunotherapy. This work demonstrates a growing immune-oncology platform for developing combination immunotherapy, widely considered the next frontier in treating cancer and the potential to deliver many breakthroughs in cancer care.

Appearances:



Festival of Biologics Day 1 @ 16:30

The Promise Of B-cell Epitope Vaccine Immunotherapies: Tackling Challenges In Combinatorial Checkpoint Inhibitor Vaccines PD-L1 and CTLA-4 B-cell epitope vaccines

  • Vaccine Strategies with Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4, TIGIT & LAG3)

  • Combination Immunotherapy HER-2 with PD-1, PD-L1 and CTLA-4 vaccines

  • Syngeneic mice models (CT26, CT26/HER-2; MC38, MC38/HER2; D2F2,D2F2/E2; 4T1;B16

  • Additive/synergistic safe anti-tumor activity

  • The future of cancer vaccines and the fundamentals of new vaccine discovery and development

last published: 31/Jan/23 09:55 GMT
last published: 31/Jan/23 09:55 GMT

back to speakers